Advertisement
Research Article| Volume 7, ISSUE 3, P507-520, July 1991

Antiarrhytmic: Agents

  • Paul E. Nolan Jr
    Correspondence
    Address reprint requests to: Paul E. Nolan, Jr, PharmD Department of Pharmacy Practice, College of Pharmacy, University of Arizona, 1703 East Mabel, Tucson, AZ 85721
    Affiliations
    Associate Professor, Department of Pharmacy Practice, University of Arizona, College of Pharmacy; and Cardiovascular Clinical Pharmacist, University Medical Center, Tucson, Arizona
    Search for articles by this author
  • Cynthia L. Raehl
    Affiliations
    Associate Professor, University of Wisconsin, School of Pharmacy; and Coordinator, Pharmacy Arrhythmia Clinic, Veceranc Administration Medical Center, Madison, Wisconsin
    Search for articles by this author
DOI:https://doi.org/10.1016/S0749-0704(18)30293-8
Antiarrhytmic: Agents
Previous ArticleNeuromusclar Blocking Agents and Sedative Drags
Next ArticleAnticonvulsant Agents
      This paper is only available as a PDF. To read, Please Download here.
      In the intensive care unit (ICU), acutely ill patients with arrhythmias are frequently treated with antiarrhythmic drugs. This review discusses the clinical conditions typically encountered in the ICU that alter the pharmacokinetics and pharmacodynamics of commonly prescribed antiarrhythmic drugs. In addition, the cardiovascular and noncardiovascular toxicities of selected agents are delineated. Potentially clinically relevant drug-drug interactions are also summarized.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Critical Care Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. ACC/AHA Task Force: Guidelines for the early management of patients with acute myocardial infarction.
        Circulation. 1990; 82: 664-707
        • Albert S.G.
        • Alves L.E.
        • Rose E.P.
        Thyroid dysfunction during chronic amiodarone therapy.
        J Am Coll Cardiol. 1987; 9: 175-183
        • Barry M.
        • Keeling P.W.N.
        • Weir D.
        • et al.
        Severity of cirrhosis and the relationship of alpha1-acid glycoprotein concentration to plasma protein binding of lidocaine.
        Clin Pharmacol Ther. 1990; 47: 366-370
        • Bauer L.A.
        • Black D.
        • Gensler A.
        • et al.
        Influence of age, renal function and heart failure on procainamide clearance and N-acetylprocainamide serum concentrations.
        Int J Clin Pharmacol Ther Toxicol. 1989; 27: 213-216
        • Beers M.H.
        • Storrie M.
        • Lee G.
        Potential adverse drug interactions in the emergency room: An issue in the quality of care.
        Ann Intern Med. 1990; 112: 61-64
        • Block J.
        • Winkle R.A.
        Hemodynamic effects of antiarrhythmic drugs.
        Am J Cardiol. 1983; 52: 14C-23C
        • Brodie M.J.
        • Feely J.
        Adverse drug reactions.
        Br Med J. 1988; 296: 845-849
        • Burton J.R.
        • Mathew M.T.
        • Armstrong P.W.
        Comparative effects of lidocaine and procainamide on acutely impaired hemodynamics.
        Am J Med. 1976; 61: 215-220
        • Campbell R.W.F.
        Assessment of the risk-benefit ratio for antiarrhythmic drug use.
        Drugs. 1988; 36: 616-632
        • Cooper J.A.D.
        • Zitnik R.J.
        • Matthay R.A.
        Mechanisms of drug-induced pulmonary disease.
        Ann Rev Med. 1988; 39: 395-404
        • Creamer J.E.
        • Nathan A.W.
        • Camm A.J.
        The proarrhythmic effects of antiarrhythmic drugs.
        Am Heart J. 1987; 114: 397-406
        • Du Souich P.
        • Erill S.
        Metabolism of procainamide and p-aminobenzoic acid in patients with chronic liver disease.
        Clin Pharmacol Ther. 1977; 22: 588-595
        • Dusman R.E.
        • Stanton M.S.
        • Miles W.M.
        • et al.
        Clinical features of amiodarone-induced pulmonary toxicity.
        Circulation. 1990; 82: 51-59
        • Dutcher J.S.
        • Strong J.M.
        • Lucas S.V.
        • et al.
        Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.
        Clin Pharmacol Ther. 1977; 22: 447-457
        • Echizen H.
        • Eichelbaum M.
        Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.
        Clin Pharmacokinet. 1986; 11: 425-449
        • Edwards D.J.
        • Axelson J.E.
        • Slaughter R.L.
        • et al.
        Factors affecting quinidine protein binding in humans.
        J Pharm Sci. 1984; 73: 1264-1267
        • Ellrodt A.G.
        • Murata G.H.
        • Riedinger M.S.
        • et al.
        Severe neutropenia associated with sustained-release procainamide.
        Ann Intern Med. 1984; 100: 197-201
        • Galeazzi R.L.
        • Omar-Amberg C.
        • Karlaganis G.
        N-acetylprocainamide kinetics in the elderly.
        Clin Pharmacol Ther. 1981; 29: 440-446
        • Gibson T.P.
        • Atkinson A.J.
        • Matusik E.
        • et al.
        Kinetics of procainamide and N-acetylprocainamide in renal failure.
        Kidney Int. 1977; 12: 422-429
        • Gottlieb S.S.
        • Kukin M.L.
        • Medina N.
        • et al.
        Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure.
        Circulation. 1990; 81: 860-864
        • Grenadier E.
        • Alpan G.
        • Keidar S.
        • et al.
        Respiratory and cardiac arrest after the administration of lidocaine into the central venous system.
        Eur Heart J. 1981; 2: 235-237
        • Jackman W.M.
        • Friday K.J.
        • Anderson J.L.
        • et al.
        The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis.
        Prog Cardiovasc Dis. 1988; 31: 115-172
        • Jacobs M.B.
        Iatrogenic disease and the primary care physician.
        Postgrad Med. 1990; 87: 108-113
        • Kastor J.A.
        Multifocal atrial tachycardia.
        N Engl J Med. 1989; 322: 1713-1717
        • Kessler K.M.
        • Humphries W.C.
        • Black M.
        • et al.
        Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol.
        Am Heart J. 1978; 96: 627-635
        • Lavie C.J.
        • Biundo J.
        • Quinet R.J.
        • et al.
        Systemic lupus erythematosus (SLE) induced by quinidine.
        Arch Intern Med. 1985; 145: 446-448
        • Lima J.J.
        • Conti D.R.
        • Goldfarb A.L.
        • et al.
        Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.
        J Pharmacokinet Biopharm. 1979; 7: 69-85
        • Manion C.V.
        • Lalka D.
        • Baer D.T.
        • et al.
        Absorption kinetics of procainamide in humans.
        J Pharm Sci. 1977; 66: 981-984
        • Meissner M.D.
        • Kay H.R.
        • Horowitz L.N.
        • et al.
        Relation of acute antiarrhythmic drug efficacy to left ventricular function in coronary artery disease.
        Am J Cardiol. 1988; 61: 1050-1055
        • Minardo J.D.
        • Heger J.J.
        • Miles W.M.
        • et al.
        Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy.
        N Engl J Med. 1988; 319: 257-262
        • Morganroth J.
        • Bigger J.T.
        Pharmacologic management of ventricular arrhythmias after the cardiac arrhythmia suppression trial.
        Am J Cardiol. 1990; 65: 1497-1503
        • Mattel S.
        • Waters D.
        What is an antiarrhythmic drug? From clinical trials to fundamental concepts.
        Am J Cardiol. 1990; 66: 96-99
        • Ochi R.P.
        • Goldenberg I.F.
        • Almquist A.
        • et al.
        Intravenous amiodarone for the rapid treatment of life-threatening ventricular arrhythmias in critically ill patients with coronary artery disease.
        Am J Cardiol. 1989; 64: 599-603
        • Olshansky B.
        • Martins J.
        • Hunt S.
        N-acetyl procainamide causing torsades de pointes.
        Am J Cardiol. 1982; 50: 1439-1441
        • Parker R.B.
        • McCollam P.L.
        Adenosine in the episodic treatment of paroxysmal supraventricular tachycardia.
        Clin Pharm. 1990; 9: 261-271
        • Perlow C.M.
        • Jain B.P.
        • Pauker S.G.
        • et al.
        Tocainide-associated interstitial pneumonitis.
        Ann Intern Med. 1981; 94: 489-490
        • Poliak P.T.
        • Sharma A.D.
        • Carruthers S.G.
        Relation of amiodarone hepatic and pulmonary toxicity to serum drug concentrations and superoxide dismutase activity.
        Am J Cardiol. 1990; 65: 1185-1191
        • Rademaker A.W.
        • Kellen J.
        • Tam Y.K.
        • et al.
        Character of adverse effects of prophylactic lidocaine in the coronary care unit.
        Clin Pharmacol Ther. 1986; 40: 71-80
        • Raeder E.A.
        • Podrid P.J.
        • Lown B.
        Side effects and complications of amiodarone therapy.
        Am Heart J. 1985; 109: 975-983
        • Ravid S.
        • Podrid P.H.
        • Lampert S.
        • et al.
        Congestive heart failure induced by six of the newer antiarrhythmic drugs.
        J Am Coll Cardiol. 1989; 14: 1326-1330
        • Reidenberg M.M.
        • Drayer D.E.
        • Levy M.
        • et al.
        Polymorphic acetylation of procainamide in man.
        Clin Pharmacol Ther. 1975; 17: 723-730
        • Roden D.M.
        • Woosley R.L.
        Tocainide.
        N Engl J Med. 1986; 315: 41-45
        • Roth R.F.
        • Itabashi H.
        • Louie J.
        • et al.
        Amiodarone toxicity: Myopathy and neuropathy.
        Am Heart J. 1990; 119: 1223-1225
        • Routledge P.A.
        The plasma protein binding of basic drugs.
        Br J Clin Pharmacol. 1986; 22: 499-506
        • Routledge P.A.
        • Barchowsky A.
        • Bjornsson T.D.
        • et al.
        Lidocaine plasma protein binding.
        Clin Pharmacol Ther. 1980; 27: 347-351
        • Shalit M.
        • Flugelman M.Y.
        • Harats N.
        • et al.
        Quinidine-induced vasculitis.
        Arch Intern Med. 1985; 145: 2051-2052
        • Shammas F.V.
        • Dickstein K.
        Clinical pharmacokinetics in heart failure. An updated review.
        Clin Pharmacokinet. 1988; 15: 94-113
        • Sheldon R.S.
        • Duff H.J.
        • Mitchell B.
        • et al.
        Effect of oral combination therapy with mexiletine and quinidine on left and right ventricular function.
        Am Heart J. 1988; 115: 1030-1036
        • Singh B.N.
        • Feld G.
        • Nademanee K.
        Arrhythmia control by selective lengthening of cardiac repolarization: Role of N-acetylprocainamide, active metabolite of procainamide.
        Angiology. 1986; 37: 930-938
        • Slater W.
        • Lampert S.
        • Podrid P.H.
        • et al.
        Clinical predictors of arrhythmia worsening by antiarrhythmic drugs.
        Am J Cardiol. 1988; 61: 349-353
        • Smyrk T.C.
        • Goellner J.R.
        • Brennan M.D.
        • et al.
        Pathology of the thyroid in amiodarone-associated thyrotoxicosis.
        Am J Surg Pathol. 1987; 11: 197-204
        • Stanton M.S.
        • Prystowsky E.N.
        • Fineberg N.S.
        • et al.
        Arrhythmogenic effects of antiarrhythmic drugs: A study of 506 patients treated for ventricular tachycardia or fibrillation.
        J Am Coll Cardiol. 1989; 14: 209-215
        • Stenson R.E.
        • Constantino R.T.
        • Harrison D.C.
        Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man.
        Circulation. 1971; 43: 205-211
        • Strong J.M.
        • Dutcher J.S.
        • Lee W-K.
        • et al.
        Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method.
        Clin Pharmacol Ther. 1975; 18: 613622
        • Swerdlow C.D.
        • Yu J.O.
        • Jacobson E.
        • et al.
        Safety and efficacy of intravenous quinidine.
        Am J Med. 1983; 75: 36-42
        • Thomson P.D.
        • MeLnon C.L.
        • Richardson J.A.
        • et al.
        Lidocaine pharmacokinetics in advanced heart failure, liver disease and renal failure in humans.
        Ann Intern Med. 1973; 73: 499-508
        • Ueda C.T.
        • Dzindzio B.S.
        Quinidine kinetics in congestive heart failure.
        Clin Pharmacol Ther. 1978; 23: 158-164
        • Viskin S.
        • Belhassen B.
        Acute management of paroxysmal atrioventricular junctional reentrant supraventricular tachycardia: Pharmacologic strategies.
        Am Heart J. 1990; 120: 180-188
        • Vlasses P.H.
        • Ferguson R.K.
        • Rocci M.L.
        • et al.
        Lethal accumulation of procainamide metabolite in severe renal insufficiency.
        Am J Nephrol. 1986; 6: 112-116
        • Waldo A.L.
        • Henthorn R.W.
        • Epstein A.E.
        • et al.
        Diagnosis and treatment of arrhythmias during and following open heart surgery.
        Med Clin North Am. 1984; 68: 1153-1169
        • Windle J.
        • Prystowsky E.N.
        • Miles W.M.
        • et al.
        Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide.
        Clin Pharmacol Ther. 1987; 41: 603-610
        • Wisenberg G.
        • Zawadowski A.G.
        • Gebhardt V.A.
        • et al.
        Effects on ventricular function of disopyramide, procainamide and quinidine as determined by radionuclide angiography.
        Am J Cardiol. 1984; 53: 1292-1297
        • Woo E.
        • Greenblatt D.J.
        A reevaluation of intravenous quinidine.
        Am Heart J. 1978; 96: 829-832
        • Zhu Y.Y.
        • Botvinick E.
        • Dae M.
        • et al.
        Gallium lung scintigraphy in amiodarone pulmonary toxicity.
        Chest. 1988; 93: 1126-1131
        • Zipes D.P.
        Specific arrhythmias: Diagnosis and treatment. Heart Disease.
        in: Braunwald E. A Textbook of Cardiovascular Medicine.ed 3. WB Saunders Co, Philadelphia1988: 658-716
        • Zito R.A.
        • Reit P.R.
        Lidocaine kinetics predicted by indocyanine green clearance.
        N Engl J Med. 1978; 298: 1160-1163

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0749-0704(18)30293-8

      Copyright

      © 1991 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX